Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: August 9, 2011
Last updated: January 20, 2013
Last verified: January 2013
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2011
  Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by Identifier (NCT Number):